PAMELA: PAM50 HER2-enriched Phenotype as a Predictor of Early Response to Neoadjuvant Lapatinib Plus Trastuzumab in Stage I to IIIA HER2-positive Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 23 Feb 2017
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab (Primary) ; Paclitaxel
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms PAMELA
- 07 Jun 2017 Biomarkers information updated
- 23 Feb 2017 Results published in the Lancet Oncology.
- 25 Jun 2016 Status changed from active, no longer recruiting to completed.